亜急性甲状腺炎に対するプレドニゾロン投与方法の検討

忠司 新生, 洋右 岡田, 桂一 鳥本 et al. · Institutional Repositories DataBase (IRDB) · 2015

The rate of recurrence of subacute thyroiditis (SAT) during prednisolone (PSL) therapy is approximately 10 to 20%. However, there is little or no information on the time period to relapse following administration of a tapered dose of PSL and the factors associated with such relapse. The aim of this study was to determine the correlation between SAT recurrence and PSL tapering regimen used in the treatment of SAT. This study was a medical record-based retrospective study and involved 26 patients (3 men, 23 women) who received PSL therapy for SAT. The primary endpoint was the association between recurrence and number of days required to taper daily PSL dose to 5 mg. The secondary endpoint was the relationship between recurrence and several variables including age, clinical score, free thyroxine, inflammatory reaction, thyroglobulin, total treatment time, total dose of PSL and presence or absence of creeping thyroiditis. The SAT recurrence rate was 15.3%. There was no significant difference in the initial PSL dose between the non-recurrence and recurrence groups (27.5 mg vs 24.5 mg, P = 0.302). However, for the primary endpoint, significant differences were found between the two groups in time required for tapering PSL to 5 mg/day (non-recurrence: 44.3 ± 15.3 days, recurrence: 19.0 ± 11.9 days, P = 0.012). None of the clinical variables evaluated correlated significantly with SAT relapse. In conclusion, to prevent recurrence of SAT, consideration should be given to the period required for PSL tapering to 5 mg/day. 亜急性甲状腺炎(SAT)に対するプレドニゾロン(PSL)治療中の再燃率は約10 - 20%である.しかしSAT の再発に至るまでの期間においてPSLの減量方法や再発に伴う因子に関する報告は無い.今回の研究ではPSLにて加療を行ったSATに対するPSLの減量方法と再燃との相関について検討することを目的とした.試験デザインは,カルテベースの後ろ向き研究で,対象は2004年1月から2013年7月にSATに対してPSLを投与した26名(男3名,女23名).主要評価項目は,再燃とPSL 5 mgに減量するまでに要した日数との関係,副次評価項目は再燃と年齢,clinical score( 活動性),free thyroxine,炎症反応,Thyroglobulin,総治療期間,総PSL量,Creepingの有無との関係とした.再燃率は15.3%であった.非再燃群と再燃群ではPSL初期投与量(27.5 mg vs 24.5 mg,P = 0.302) に有意差を認めない.しかし,主要評価項目:PSL 5 mgに減量するまでの日数(非再燃群:44.3 ± 15.3日 vs 再燃群:19.0 ± 11.9日,P = 0.012)に有意差を認めた.副次評価項目:その他の臨床的項目とSATの再燃との間に有意な相関は認めなかった.結論として,SATの再燃を起こさないためには,PSL減量日数に留意すべきであり,PSL 5 mgまでの減量には十分時間をかけるべきである.

Cited by 0 works.

Authors